Multiple Myeloma

Experts from Columbia University highlight approvals in CLL, bispecific antibodies in multiple myeloma, and actionable biomarkers in DLBCL.

The adoption of bispecific antibodies in the community setting remains a great unmet need in multiple myeloma, according to Rajshekhar Chakraborty, MD.

Education, REMS certification, and long-term management are key barriers to the widespread adoption of bispecific antibodies in the community setting.

Investigators will present detailed findings from the phase 3 SUCCESSOR-2 trial at a later medical meeting.

Having a tool belt with iberdomide and many other combinable drugs may help lead to a cure in multiple myeloma, said Sagar Lonial, MD, FACP, FASCO.

The Commissioner’s National Priority Voucher has been granted by the FDA to teclistamab plus daratumumab hyaluronidase-fihj in relapsed/refractory multiple myeloma.

If approved, iberdomide plus daratumumab/dexamethasone would offer patients more choices, according to Sagar Lonial, MD, FACP, FASCO.

Data from a phase 1b/2 study may support further assessment of AZD0120 in earlier treatment settings for patients with multiple myeloma.

An effective regimen that partly incorporates oral therapy may be favorable from a patient convenience perspective, said Sagar Lonial, MD, FACP, FASCO.

Investigators of the phase 2 MOMENTUM trial will enroll and assign approximately 100 patients to receive cemsidomide at 100 µg.

Data from the EXCALIBER-RRMM trial support the application for iberdomide plus standard therapy in this relapsed/refractory multiple myeloma population.

Developing small molecules that target t(4;14) will be important in multiple myeloma care, according to Saad Z. Usmani, MD, MBA, FACP, FASCO.

Discover how stem cell transplant still deepens myeloma remission, guided by MRD and paired with CAR‑T, bispecifics, and smarter maintenance.

In the future, the multiple myeloma field may gradually shift away from a continuous therapy model to more fixed-duration approaches.

The immune system is a “critical player” in the emergence and outcome of multiple myeloma, according to Manoj Bhasin, PhD, MS.

From key clinical trial updates to reports on treatment disparities, the 2026 Tandem Meetings saw several critical developments in multiple myeloma.

Research may support the development of more comprehensive risk-stratification models accounting for different tumor-intrinsic factors.

Potential FDA approval of teclistamab plus daratumumab may offer another option in the multiple myeloma armamentarium, said Surbhi Sidana, MD.

A new guideline from ASCO and Ontario Health conditionally recommends the use of daratumumab for patients with high-risk smoldering multiple myeloma.

Data from the phase 3 CEPHEUS trial support the approval of the daratumumab-based regimen among patients with newly diagnosed multiple myeloma.

Investigators are currently assessing IBI3003 among patients with relapsed/refractory multiple myeloma in a phase 1/2 trial.

Findings show that age also represents an important driver for select pathologic genomic events differing at the presentation of disease by sex.

According to the FDA, randomized trials are preferred when assessing MRD to support accelerated approvals in multiple myeloma.

Safety data from the phase 1 LUMMICAR study 1 show no high-grade CRS or any-grade ICANS among patients with myeloma who received zevorcabtagene autoleucel.

Data from CARTITUDE-4 show that cilta-cel can improve outcomes for patients with lenalidomide-refractory multiple myeloma as early as first relapse.